For Sufferers of Atopic Dermatitis, It’s Not Just a Rash
Atopic dermatitis, a type of Eczema, may seem like just a skin condition, but to sufferers it’s much, much more. We met one Pfizer scientist trying to change all that.
Atopic dermatitis is easy to write-off as unworthy of serious medical pursuit. It’s not life threatening, nor is it incredibly physically painful. But for many people, the lack of options causes daily anxiety. An ignorance of the condition may breed insensitive comments and leave many feeling stigmatized and alone.
Narrated by Dr. Freda C. Lewis-Hall, Chief Medical Officer of Pfizer, this episode of Cure Hunters caught up with Jean Beebe, VP of clinical development at Pfizer. She shared her point of view on the disease and why she’s not interested in baby steps when it comes to finding a potential cure. Check out the video above and keep tuning in to Cure Hunters.
More Cure Hunters episodes:
Episode 1 | How Are Medicines Made?
ADVERTISEMENT
Episode 2 | Harnessing The Immune System To Fight Cancer
Get the best of The Beast delivered right to your inbox
By clicking “SUBSCRIBE” you agree to our Terms of Use and Privacy Policy.
Episode 4 | NASH: The Silent Killer
Episode 5 | Precision Medicine: Targeting Cancer at The Source
Episode 6 | Building a Mirror Molecule
Episode 7 | Hunting Rare Diseases
Episode 8 | Take Your Breath Away
Episode 9 | Clinical Trials: Driving The Hunt Forward
Episode 10 | A Constant Threat
Episode 11 | Engineering Health
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.